<DOC>
	<DOCNO>NCT01026701</DOCNO>
	<brief_summary>The purpose study measure marker relate bone metabolism use bortezomib injection patient multiple myeloma evaluate effect bortezomib injection bone disease .</brief_summary>
	<brief_title>Observational Study Effects Intravenous Bortezomib Has Osteoblast ( Cell That Responsible Bone Formation ) Activity Multiple Myeloma Patients .</brief_title>
	<detailed_description>Among several symptom patient multiple myeloma , bone disease one common symptom approximately 80 percent patient experience . Multiple myeloma different tumor several osteoclast activate factor ( OAF ) release multiple myeloma cell resorb bone , time , activation osteoblast inhibit , lead unbalance breakdown formation bone . Activation osteoclast inhibition osteoblast brings bone fracture , osteoporosis , hypercalcemia , bone pain spinal cord compression . Those symptom directly related patient ' quality life . Therefore , important therapeutic target multiple myeloma . Various type bisphosphonate agent use treatment bone disease patient multiple myeloma . This prospective ( study participant identify follow forward time ) , multi-center , Phase 4 , observational study ( study record specific event occur without intervention researcher ) order analyze change bone metabolism marker ( DKK-1 , sRANKL , OPG , sRANKL/OPG , bALP , OC ) use bortezomib injection use enzyme-linked immunosorbent assay ( ELISA ) serum . The adverse event assess National Cancer Institute Common Terminology Criteria Adverse Events Version 3.0 ( NCI CTCAE V3 ) . The patient receive bortezomib injection vein 1.3 mg/m2 twice week 21 day usual clinical practice .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Among patient newly prescribe bortezomib injection secondary agent treatment multiple myeloma , agree provide information include . Patients hypersensitive study drug component study drug history hypersensitivity Patients severe hepatic impairment Women pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Osteoblst effect</keyword>
	<keyword>Velcade</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Multjple Myeloma</keyword>
</DOC>